AMLX - Amylyx Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$31.50
DETAILS
HIGH:
$40.00
LOW:
$24.00
MEDIAN:
$31.00
CONSENSUS:
$31.50
DOWNSIDE:
10.28%
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | |||||||
| Revenue | 0 | 87.4 | 380.8 | 22.2 | 0 | 0.7 | 1.4 |
| Cost of Revenue | 0.5 | 42.2 | 25.4 | 3.0 | 0 | 24.6 | 11.9 |
| Gross Profit | (0.5) | 45.2 | 355.3 | 19.2 | 0 | (23.9) | (10.5) |
| Operating Expenses | |||||||
| R&D Expenses | 90.4 | 104.1 | 128.2 | 93.5 | 44.0 | 24.6 | 11.9 |
| SG&A Expenses | 62.9 | 114.3 | 188.4 | 127.1 | 38.9 | 15.1 | 3.1 |
| Other Expenses | 0 | 141.5 | 0 | 0 | (0.3) | (24.6) | (1.4) |
| Operating Expenses | 152.8 | 359.9 | 316.5 | 220.6 | 82.7 | 15.1 | 13.6 |
| Operating Income | |||||||
| Operating Income | (153.3) | (314.7) | 38.8 | (201.3) | (82.7) | (39.0) | (13.6) |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 2.3 | 1.3 |
| Interest Income | 9.3 | 13.8 | 16.2 | 4.3 | 0.0 | 0.0 | 0.2 |
| Profitability | |||||||
| EBITDA | (144.2) | (291.0) | 55.4 | (197.1) | (87.9) | (39.0) | 1.1 |
| EBIT | (144.7) | (291.9) | 54.3 | (197.6) | (87.9) | (39.0) | (12.4) |
| Income Before Tax | (144.7) | (302.1) | 54.3 | (197.6) | (87.9) | (42.3) | (13.7) |
| Income Tax Expense | 0.0 | (0.4) | 5.0 | 0.8 | 0 | 0 | 0 |
| Net Income | (144.7) | (301.7) | 49.3 | (198.4) | (87.9) | (42.3) | (14.8) |
| Per Share Data | |||||||
| EPS (Basic) | -1.53 | -4.43 | 0.73 | -2.98 | -1.52 | -0.79 | -0.26 |
| EPS (Diluted) | -1.53 | -4.43 | 0.70 | -2.98 | -1.52 | -0.79 | -0.26 |
| Shares Outstanding | 94.6 | 68.1 | 67.2 | 66.5 | 57.9 | 56.5 | 56.5 |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Current Assets | |||||||
| Cash & Cash Equivalents | 226.7 | 77.4 | 170.2 | 62.5 | 50.2 | 12.9 | 3.1 |
| Short-Term Investments | 90.3 | 99.1 | 201.2 | 284.4 | 45.9 | 0 | 0 |
| Net Receivables | 0.1 | 0.4 | 40.0 | 15.3 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 38.3 | 9.8 | 0 | 0 | 0 |
| Other Current Assets | 6.6 | 12.5 | 14.9 | 10.1 | 3.4 | 0 | 0.0 |
| Total Current Assets | 323.7 | 189.4 | 464.7 | 382.1 | 105.0 | 13.6 | 3.2 |
| Non-Current Assets | |||||||
| Property, Plant & Equipment | 5.5 | 2.7 | 6.4 | 8.1 | 0.5 | 0.2 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0.2 | 0 |
| Other Non-Current Assets | 3.5 | 1.5 | 46.4 | 1.2 | 0.2 | 0.1 | 0.0 |
| Total Non-Current Assets | 9.0 | 4.2 | 52.8 | 9.3 | 0.7 | 0.5 | 0.0 |
| Total Assets | 332.6 | 193.6 | 517.5 | 391.5 | 105.6 | 14.1 | 3.2 |
| Current Liabilities | |||||||
| Account Payables | 3.5 | 2.9 | 22.1 | 6.3 | 4.4 | 3.6 | 2.2 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 10.1 | 10.0 | 40.9 | 15.2 | 4.3 | 0 | 0.7 |
| Total Current Liabilities | 22.7 | 28.4 | 82.0 | 46.6 | 17.4 | 7.3 | 4.5 |
| Non-Current Liabilities | |||||||
| Long-Term Debt | 4.7 | 0 | 0 | 0 | 0 | 1.4 | 14.9 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 239.4 | 72.1 | 9.1 |
| Total Non-Current Liabilities | 4.7 | 0.5 | 2.0 | 4.2 | 239.4 | 73.5 | 24.0 |
| Total Liabilities | 27.4 | 28.9 | 84.0 | 50.8 | 256.8 | 80.8 | 28.6 |
| Stockholders' Equity | |||||||
| Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Retained Earnings | (751.4) | (606.7) | (304.9) | (354.2) | (155.8) | (67.9) | (25.6) |
| Accumulated Other Comprehensive Income | 0.4 | (0.1) | 0.2 | (0.1) | 0.0 | (72.1) | 0 |
| Total Stockholders' Equity | 305.3 | 164.8 | 433.4 | 340.6 | (151.2) | (66.7) | (25.4) |
| Total Liabilities & Equity | 332.6 | 193.6 | 517.5 | 391.5 | 105.6 | 14.1 | 3.2 |
| Debt Metrics | |||||||
| Total Debt | 6.0 | 2.0 | 4.2 | 6.3 | 0 | 1.4 | 14.9 |
| Net Debt | (220.7) | (75.4) | (166.0) | (56.2) | (50.2) | (11.5) | 11.9 |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Net Income | (144.7) | (301.7) | 49.3 | (198.4) | (87.9) | (42.3) | (13.7) |
| Depreciation & Amortization | 0.5 | 0.9 | 1.1 | 0.5 | 0.1 | 0.0 | 0 |
| Stock-Based Compensation | 27.6 | 33.0 | 37.2 | 21.7 | 3.1 | 0.2 | 0.1 |
| Change in Working Capital | (1.1) | (45.8) | (65.7) | (1.6) | 4.6 | 2.6 | 3.5 |
| Other Non-Cash Items | (5.7) | 146.0 | (9.9) | (2.1) | 5.3 | 2.7 | (0.6) |
| Operating Cash Flow | (123.3) | (167.6) | 11.9 | (179.9) | (74.8) | (36.7) | (10.7) |
| Investing Activities | |||||||
| Capital Expenditure | (0.1) | (0.2) | (1.2) | (2.5) | (0.4) | (0.2) | 0 |
| Acquisitions | 0 | 0 | 0 | 236.5 | 0 | 0 | 0 |
| Purchases of Investments | (231.8) | (232.0) | (300.8) | (415.9) | (49.1) | 0 | 0 |
| Sales/Maturities of Investments | 246 | 344 | 394.1 | 179.4 | 3 | 0 | 0 |
| Other Investing Activities | 0 | (36.2) | 0 | (236.5) | 0 | 0 | 0 |
| Investing Cash Flow | 14.0 | 75.7 | 92.1 | (239.0) | (46.4) | (0.2) | 0 |
| Financing Activities | |||||||
| Net Debt Issuance | 0 | 0 | 0 | 0 | 25.9 | 16.8 | 0.6 |
| Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.4) | (1.8) | (3.3) | (0.7) | (2.4) | 0.0 | 0 |
| Financing Cash Flow | 257.0 | 0.3 | 3.5 | 431.8 | 158.5 | 46.8 | 0.7 |
| Cash Position | |||||||
| Net Change in Cash | 148.8 | (92.1) | 107.7 | 12.9 | 37.3 | 10.0 | 3.1 |
| Cash at Beginning | 78.8 | 170.9 | 62.5 | 50.4 | 13.1 | 3.1 | 0 |
| Cash at End | 227.6 | 78.8 | 170.2 | 63.2 | 50.4 | 13.1 | 3.1 |
| Free Cash Flow | (123.5) | (167.8) | 10.7 | (182.4) | (75.2) | (36.8) | (10.7) |
| Key Metrics | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 0 | 87.4 | 380.8 | 22.2 | 0 | 0.7 | 1.4 |
| Gross Profit | (0.5) | 45.2 | 355.3 | 19.2 | 0 | (23.9) | (10.5) |
| Operating Income | (153.3) | (314.7) | 38.8 | (201.3) | (82.7) | (39.0) | (13.6) |
| Net Income | (144.7) | (301.7) | 49.3 | (198.4) | (87.9) | (42.3) | (14.8) |
| EPS (Diluted) | -1.53 | -4.43 | 0.70 | -2.98 | -1.52 | -0.79 | -0.26 |
| Balance Sheet | |||||||
| Cash & Equivalents | 226.7 | 77.4 | 170.2 | 62.5 | 50.2 | 12.9 | 3.1 |
| Total Assets | 332.6 | 193.6 | 517.5 | 391.5 | 105.6 | 14.1 | 3.2 |
| Total Debt | 6.0 | 2.0 | 4.2 | 6.3 | 0 | 1.4 | 14.9 |
| Stockholders' Equity | 305.3 | 164.8 | 433.4 | 340.6 | (151.2) | (66.7) | (25.4) |
| Cash Flow | |||||||
| Operating Cash Flow | (123.3) | (167.6) | 11.9 | (179.9) | (74.8) | (36.7) | (10.7) |
| Capital Expenditure | (0.1) | (0.2) | (1.2) | (2.5) | (0.4) | (0.2) | 0 |
| Free Cash Flow | (123.5) | (167.8) | 10.7 | (182.4) | (75.2) | (36.8) | (10.7) |